

Masao Toyoda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9164524/publications.pdf>

Version: 2024-02-01

74
papers

1,825
citations

304368

22
h-index

276539

41
g-index

75
all docs

75
docs citations

75
times ranked

2838
citing authors

#	ARTICLE	IF	CITATIONS
1	Polypharmacy influences the renal composite outcome in patients treated with sodium-glucose cotransporter 2 inhibitors. <i>Clinical and Translational Science</i> , 2022, , .	1.5	2
2	Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109231.	1.1	4
3	Concomitant treatment with insulin and sodium-glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity score-matched analysis. <i>Journal of Diabetes Investigation</i> , 2022, , .	1.1	1
4	Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY). <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 1084-1092.	1.3	14
5	Blood pressure after treatment with sodium-glucose cotransporter-2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models. <i>Journal of Diabetes Investigation</i> , 2021, 12, 74-81.	1.1	8
6	Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 110-119.	2.4	11
7	Assessment of the accuracy of an intermittent-scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (<sc>AIDT2H</sc>) study. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 586-594.	0.4	15
8	Genome-wide association studies identify two novel loci conferring susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes. <i>Human Molecular Genetics</i> , 2021, 30, 716-726.	1.4	13
9	Sodium-glucose cotransporter-2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type-2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1408-1416.	1.1	9
10	The evaluation of noninferiority for renal composite outcomes between sodium-glucose cotransporter inhibitors in Japan. <i>Primary Care Diabetes</i> , 2021, 15, 1058-1062.	0.9	2
11	Regulation of Blood Pressure and Phosphorylation of Î²1-integrin in Renal Tissue in a Rat Model of Diabetic Nephropathy. <i>Tokai Journal of Experimental and Clinical Medicine</i> , 2021, 46, 172-179.	0.4	1
12	The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Journal of Diabetes Research</i> , 2021, 1-7.	1.0	1
13	Development and Validation of the Continuous Subcutaneous Insulin Infusion-Related Quality-of-Life (CSII-QOL) Scale. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 216-221.	2.4	5
14	Caution is required for the evaluation of the accuracy of continuous glucose monitoring devices. <i>Journal of Diabetes Investigation</i> , 2020, 11, 255-255.	1.1	2
15	Nivolumab-induced fulminant type-1 diabetes with precipitous fall in C-peptide level. <i>Journal of Diabetes Investigation</i> , 2020, 11, 748-749.	1.1	9
16	The influence of long-term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2020, 22, 2306-2314.	1.0	5
17	Relationship between Serum Antioxidative Vitamin Concentrations and Type 2 Diabetes in Japanese Subjects. <i>Journal of Nutritional Science and Vitaminology</i> , 2020, 66, 289-295.	0.2	6
18	Glycemic Control After Kidney Transplantation Using Sensor-augmented Insulin Pump Therapy in a Patient with Slowly Progressive Type 1 Diabetes Mellitus. <i>Tokai Journal of Experimental and Clinical Medicine</i> , 2020, 45, 49-52.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Importance of the Evaluation of Renal Function for the Prevention of Hypoglycemia in Elderly Diabetes Patients. Tokai Journal of Experimental and Clinical Medicine, 2020, 45, 139-143.	0.4	0
20	Behavior Modification Maintenance with Long-Term Blood Glucose and Weight Management in Prader-Willi Syndrome Complicated with Diabetes: Team Management Approach Combined with Pharmacological Treatment. Case Reports in Medicine, 2019, 2019, 1-7.	0.3	4
21	The Effect of High-concentration Insulin Glargine on the Quality of Life of Patients with Type 2 Diabetes Mellitus: A Pre-post Study (HIGH-QOL STUDY). Internal Medicine, 2019, 58, 2943-2948.	0.3	1
22	Clinical comparison of tofogliflozin and empagliflozin based on an analysis of 24-h accumulated urine in Japanese patients with type 2 diabetes mellitus. Obesity Medicine, 2019, 14, 100088.	0.5	2
23	Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2019, 39, 631-641.	1.1	21
24	N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≤ 30 mL/min/1.73 m ² . Clinical and Experimental Nephrology, 2019, 23, 1004-1012.	0.7	5
25	A Liquid-Based Cytology System, without the Use of Cyto centrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy. Journal of Diabetes Research, 2019, 2019, 1-7.	1.0	6
26	Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease. Journal of Diabetes Research, 2019, 2019, 1-7.	1.0	6
27	Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring. Clinical and Experimental Hypertension, 2019, 41, 637-644.	0.5	4
28	Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease. Diabetes and Vascular Disease Research, 2019, 16, 103-107.	0.9	13
29	The Current Intermittent-Scanning CGM Device Situation in Japan: Only Adjunctive Use to SMBG Is Approved and the Latest Health Insurance Coverage Details. Journal of Diabetes Science and Technology, 2018, 12, 729-730.	1.3	5
30	A variant within the FTO confers susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes. PLoS ONE, 2018, 13, e0208654.	1.1	30
31	Raltegravir-associated Diabetic Ketoacidosis in a Patient with HIV Infection: A Case Report. Tokai Journal of Experimental and Clinical Medicine, 2018, 43, 19-23.	0.4	7
32	Detection of Autonomic Nervous System Abnormalities in Diabetic Patients by 24-hour Ambulatory Blood Pressure Monitoring. Tokai Journal of Experimental and Clinical Medicine, 2018, 43, 97-102.	0.4	2
33	Factors affecting consultation length in a Japanese diabetes practice. Diabetes Research and Clinical Practice, 2017, 126, 54-59.	1.1	12
34	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinology, 2017, 5, 951-964.	5.5	228
35	Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor. Internal Medicine, 2017, 56, 1673-1678.	0.3	7
36	Favorable Effect on Blood Volume Control in Hemodialysis Patients with Type 2 Diabetes after Switching from Insulin Therapy to Liraglutide, a Human Glucagon-like Peptide-1 Analog-Results from a Pilot Study in Japan-. Tokai Journal of Experimental and Clinical Medicine, 2017, 42, 52-57.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Exercise Therapy for Management of Type 2 Diabetes Mellitus: Superior Efficacy of Activity Monitors over Pedometers. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-7.	1.0	20
38	Upregulation of $\alpha 3 \beta 1$ -Integrin in Podocytes in Early-Stage Diabetic Nephropathy. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-7.	1.0	27
39	The Prevalence of 25-hydroxyvitamin D Deficiency in Japanese Patients with Diabetic Nephropathy. <i>Internal Medicine</i> , 2016, 55, 2555-2562.	0.3	15
40	Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-associated acute kidney injury. <i>Scientific Reports</i> , 2015, 5, 14471.	1.6	40
41	Predictors of response to liraglutide in Japanese type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 451-457.	1.1	16
42	Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients. <i>Diabetology International</i> , 2014, 5, 98-104.	0.7	0
43	Survey of urinary albumin level and estimated GFR in Japanese patients with type 2 diabetes mellitus. <i>Diabetology International</i> , 2013, 4, 101-105.	0.7	0
44	Replication study for the association of 3 SNP loci identified in a genome-wide association study for diabetic nephropathy in European type 1 diabetes with diabetic nephropathy in Japanese patients with type 2 diabetes. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 866-871.	0.7	16
45	Effects of Liraglutide, a Human Glucagon-like Peptide-1 Analogue, on Body Weight, Body Fat Area and Body Fat-related Markers in Patients with Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , 2013, 52, 1029-1034.	0.3	52
46	The Influence of a Single Nucleotide Polymorphism within CNDP1 on Susceptibility to Diabetic Nephropathy in Japanese Women with Type 2 Diabetes. <i>PLoS ONE</i> , 2013, 8, e54064.	1.1	23
47	Clinical Significance of Fibroblast-Specific Protein-1 Expression on Podocytes in Patients with Focal Segmental Glomerulosclerosis. <i>Nephron Clinical Practice</i> , 2012, 120, c1-c7.	2.3	10
48	Expression of transcription factor Snai1 and tubulointerstitial fibrosis in progressive nephropathy. <i>Journal of Nephrology</i> , 2012, 25, 233-239.	0.9	24
49	Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis. <i>Journal of Nephrology</i> , 2012, 25, 989-995.	0.9	12
50	Association between single nucleotide polymorphisms within genes encoding sirtuin families and diabetic nephropathy in Japanese subjects with type 2 diabetes. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 381-390.	0.7	63
51	Effects of Multiple Factorial Intervention on Ambulatory BP Profile and Renal Function in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy – A Pilot Study. <i>Clinical and Experimental Hypertension</i> , 2011, 33, 255-263.	0.5	12
52	Replication Study for the Association Between Four Loci Identified by a Genome-Wide Association Study on European American Subjects With Type 1 Diabetes and Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2010, 59, 2075-2079.	0.3	52
53	A Single Nucleotide Polymorphism in <i>KCNQ1</i> Is Associated With Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 842-846.	4.3	25
54	A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes. <i>PLoS Genetics</i> , 2010, 6, e1000842.	1.5	81

#	ARTICLE	IF	CITATIONS
55	Expression of angiotensin II type 1 receptor-interacting molecule in normal human kidney and IgA nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, F720-F731.	1.3	23
56	Epithelial-Mesenchymal Transition as a Potential Explanation for Podocyte Depletion in Diabetic Nephropathy. <i>American Journal of Kidney Diseases</i> , 2009, 54, 653-664.	2.1	156
57	Lectin-Like Oxidized LDL Receptor-1 (LOX-1) Expression in the Tubulointerstitial Area Likely Plays an Important Role in Human Diabetic Nephropathy. <i>Internal Medicine</i> , 2009, 48, 189-194.	0.3	29
58	Hypertrophy and Loss of Podocytes in Diabetic Nephropathy. <i>Internal Medicine</i> , 2009, 48, 1615-1620.	0.3	39
59	Expression of Alpha-actinin-4 in Human Diabetic Nephropathy. <i>Internal Medicine</i> , 2008, 47, 1099-1106.	0.3	18
60	Long-Term Intensive Insulin Therapy for Japanese Patients with Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , 2008, 47, 2109-2115.	0.3	3
61	Podocyte Detachment and Reduced Glomerular Capillary Endothelial Fenestration in Human Type 1 Diabetic Nephropathy. <i>Diabetes</i> , 2007, 56, 2155-2160.	0.3	234
62	Interaction of Alpha-Actinin-4 with Class I PxxP Motif-Containing OK/SW-CL.16 Protein. <i>Nephron Experimental Nephrology</i> , 2007, 107, e65-e72.	2.4	3
63	A Retrospective Study on the Efficacy of Corticosteroid-Alone Therapy in Membranous Nephropathy Patients. <i>Internal Medicine</i> , 2007, 46, 1641-1645.	0.3	3
64	Relationship between the Expression of Advanced Glycation End-Products (AGE) and the Receptor for AGE (RAGE) mRNA in Diabetic Nephropathy. <i>Internal Medicine</i> , 2006, 45, 435-441.	0.3	48
65	A Case with Membranous Lupus Nephritis Developing after a Twenty-year Remission of Membranoproliferative Glomerulonephritis. <i>Internal Medicine</i> , 2006, 45, 531-536.	0.3	2
66	Expression of human nephrin mRNA in diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 380-385.	0.4	62
67	High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. <i>Kidney International</i> , 2004, 66, 1107-1114.	2.6	79
68	Glomerular expression of platelet-derived growth factor (PDGF)-A, -B chain and PDGF receptor- α , - β in human diabetic nephropathy. <i>Clinical and Experimental Nephrology</i> , 2004, 8, 36-42.	0.7	43
69	Interaction of the spectrin-like repeats of alpha-actinin-4 with humanin peptide. <i>Clinical and Experimental Nephrology</i> , 2004, 8, 331-338.	0.7	12
70	Glomerular expression of connective tissue growth factor mRNA in various renal diseases. <i>Nephrology</i> , 2003, 8, 92-97.	0.7	9
71	Specific Tissue Distribution of Megsin, a Novel Serpin, in the Glomerulus and Its Up-Regulation in IgA Nephropathy. <i>Biochemical and Biophysical Research Communications</i> , 2001, 286, 1098-1106.	1.0	26
72	Evaluation of Renal Biopsy Samples of Patients with Diabetic Nephropathy.. <i>Internal Medicine</i> , 2001, 40, 1077-1084.	0.3	44

#	ARTICLE	IF	CITATIONS
73	Expression of Megsin mRNA, a Novel Mesangium-Predominant Gene, in the Renal Tissues of Various Glomerular Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 2606-2613.	3.0	39
74	The Importance of Patient and Family Engagement, the Needs for Self-Monitoring of Blood Glucose (SMBG) – Our Perspectives Learned Through a Story of SMBG Assistive Devices Made by a Husband of the Patient with Diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 1627-1638.	1.1	0